EDITORIAL

Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

The Open Respiratory Medicine Journal 15 Mar 2022 EDITORIAL DOI: 10.2174/18743064-v16-e2202040

Editorial

The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.

Keywords: Vaccines, mRNA Vaccines, SARS-CoV-2, COVID-19, Cerebral venous embolism, Delta variant, Myocarditis.
Fulltext HTML PDF ePub
1800
1801
1802
1803
1804